Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization
Status:
Withdrawn
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
Antibody mediated rejection (AMR) post transplant contributes to poor long term outcomes
after lung transplantation. Additionally, high antibodies detected pre transplant in
candidates limit donor availability for lung transplant. This proposal would include
belatacept in a multi-therapy regimen. Open label study with two patient cohorts for safety
and efficacy of belatacept in a multi-modal protocol. The two patient cohorts are an AMR
post-transplant cohort and pre-transplant desensitization cohort. A total of 10 patients will
be enrolled.The primary objection is drug tolerability and secondary objectives are antibody
measurements and allograft function.